Hemosol Receives Extension from NASDAQ to Regain Compliance With Listing Requirements
December 21 2004 - 4:00PM
PR Newswire (US)
Hemosol Receives Extension from NASDAQ to Regain Compliance With
Listing Requirements TORONTO, Dec. 21 /PRNewswire-FirstCall/ --
Hemosol Corp. (NASDAQ:HMSLNASDAQ: TSX:NASDAQ:HML) today announced
that it received from NASDAQ an additional 180 day extension (to
June 16, 2005) to regain compliance with NASDAQ's minimum bid price
requirement. The notice of the 180-day extension follows an initial
notice from NASDAQ on June 21, 2004 that the Company had until
December 20, 2004 to regain compliance with NASDAQ's minimum bid
price requirement and that the Company may qualify as of such date
for an additional 180 day extension of the compliance period. About
Hemosol Hemosol is a biopharmaceutical company focused on the
development and manufacturing of biologics, particularly
blood-related proteins. Hemosol has a broad range of novel
therapeutic products in development, including oxygen therapeutics
and protein-based therapeutics to treat certain infectious
diseases, cancers and anemia. For more information visit Hemosol's
website at http://www.hemosol.com/. Hemosol's common shares are
listed on the NASDAQ Stock Market under the trading symbol "HMSL"
and on the Toronto Stock Exchange under the trading symbol "HML".
Certain statements concerning Hemosol's future prospects are
"forward- looking statements" within the meaning of the United
States Private Securities Litigation Reform Act of 1995 and other
applicable securities legislation. There can be no assurances that
future results will be achieved, and actual results could differ
materially from forecasts and estimates. Important factors that
could cause actual results to differ materially from forecasts and
estimates include, but are not limited to: Hemosol's ability to
successfully implement the Cascade technology and commercialize
products derived therefrom; Hemosol's ability to obtain additional
financing; Hemosol's ability to obtain regulatory approvals for its
products; Hemosol's ability to successfully complete clinical
trials for its products; Hemosol's ability to enter into
satisfactory arrangements for the supply of materials used in its
manufacturing operations and the sale of resulting products to
customers; technical, manufacturing or distribution issues; the
competitive environment for Hemosol's products and services; the
degree of market penetration of Hemosol's products; Hemosol's
ability to attract and retain clients for its bio-manufacturing
services; and other factors set forth in filings with Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission. These risks and uncertainties, as well as
others, are discussed in greater detail in the filings of Hemosol
with Canadian securities regulatory authorities and the U.S.
Securities and Exchange Commission. Hemosol makes no commitment to
revise or update any forward-looking statements in order to reflect
events or circumstances after the date any such statement is made.
DATASOURCE: Hemosol Corp. CONTACT: Jason Hogan, Investor &
Media Relations, (416) 361-1331, 800-789-3419, (416) 815 0080 fax,
, http://www.hemosol.com/; Archived images on this organization are
available through CNW E-Pix at http://www.newswire.ca/. Images are
free to members of The Canadian Press. To request a free copy of
this organization's annual report, please go to
http://www.newswire.ca/ and click on reports@cnw.
Copyright
Hemosol (NASDAQ:HMSL)
Historical Stock Chart
From Apr 2024 to May 2024
Hemosol (NASDAQ:HMSL)
Historical Stock Chart
From May 2023 to May 2024